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Abstract
Progressive increase of mean age and life expectancy in both industrialized and emerging societies parallels an
increment of chronic degenerative diseases (CDD) such as cancer, cardiovascular, autoimmune or neurodegenera-
tive diseases among the elderly. CDD are of complex diagnosis, difficult to treat and absorbing an increasing pro-
portion in the health care budgets worldwide. However, recent development in modern medicine especially in
genetics, proteomics, and informatics is leading to the discovery of biomarkers associated with different CDD that
can be used as indicator of disease’s risk in healthy subjects. Therefore, predictive medicine is merging and medical
doctors may for the first time anticipate the deleterious effect of CDD and use markers to identify persons with
high risk of developing a given CDD before the clinical manifestation of the diseases. This innovative approach
may offer substantial advantages, since the promise of personalized medicine is to preserve individual health in
people with high risk by starting early treatment or prevention protocols. The pathway is now open, however the
road to an effective personalized medicine is still long, several (diagnostic) predictive instruments for different CDD
are under development, some ethical issues have to be solved. Operative proposals for the heath care systems are
now needed to verify potential benefits of predictive medicine in the clinical practice. In fact, predictive diagnos-
tics, personalized medicine and personalized therapy have the potential of changing classical approaches of
modern medicine to CDD.
Introduction
A dramatic increase in mean life span and life expec-
tancy, coupled with a significant reduction in early mor-
tality, has lead to a substantial increment in the number
of the elderly population in contemporary societies. This
demographic picture parallels the merging of a new epi-
demic characterized by chronic age related or degenera-
tive diseases (CDD). Clinical diagnosis and therapy of
these diseases imply multidisciplinary medical
approaches and their cost is progressively increasing.
Most CDD have complex aetiology and pathogenesis. In
fact, human CDD are often the consequence of a com-
plex interplay of genetic, epigenetic and environmental
factors. Moreover current therapies are administered
uniformly across a heterogeneous spectrum of disease
aetiology, severity and genetic background. However, as
large scale investigation platform become a mainstream,
modern medicine has the opportunity to expand its
medical instrumentation to include molecular pheno-
types, genetic background and biomarkers to distinguish
clinical subtypes of a single disease to better tailor both
potential prevention strategies and/or early intervention
protocols for CDD.
Therefore, the future treatment of CDD may contem-
plate primary, secondary or tertiary prevention. Primary
prevention reduces diseases in a population by lowering
exposure to casual agents or promoting host resistance
and may lead to a decrease in age specific incidence rate
or in a rise in the mean age at onset of a given CDD.
Secondary prevention limits progression and recurrence
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of a disease by early case detection, diagnosis and treat-
ment and reduces the disease prevalence. Tertiary pre-
vention ameliorates the symptoms and tissue damages
associated to a given CDD by containing individual dis-
ability and dependency and maintaining an acceptable
quality of life.
Predictive diagnostics are merging from the acquisi-
tion of new phenotypic and genetic markers associated
with CDD. This markers are generated by a panomic
approach to biology of diseases such as genome wide
association study, transcriptomics, proteomics and meta-
bolomics. These disciplines attempt to capture the large
output of an organism DNA, RNA, proteins and meta-
bolites with the view that the whole is often greater
than the sum of its parts and subtle critical information
may be obtained by these methodological sophisticated
approaches [1,2]. Recent advances in computational ana-
lysis has increased data availability for predictive medi-
cine of CDD [3].
It is known that individuals are distinguished form
one another by 0.1% difference in the nucleotide
sequence of human genome. These difference are often
in the form of a single base pair or single nucleotide
polymorphism (SNP). Individual SNP usually causes
only a modest change in the cognate protein concentra-
tion or function and is of limited information for dis-
ease’s risk evaluation. Therefore, the concomitant
presence of several SNPs is more informative to deter-
mine susceptibility to disease development in polygenic
human condition such as CDD. Finally, in complex
genetic diseases the genotype confer susceptibility, but
the clinical presentation of the disease depends upon
interactions of several different genes with environmen-
tal factors.
Proteomic studies may then confirming and extending
the findings of functional genomic investigations and
provide novel markers for CDD.
Complementary to this global, non-hypothesis-driven
methodologies, the candidate gene or marker approach
evaluates individual marker in association with CDD
based on a prior understanding of its role in the disease.
Genetic investigations on CDD are collecting useful
information regarding genes associated with the dis-
ease risk. The goal will be to identify non symptomatic
individual with high susceptibility for the disease who
may benefit from prevention or early intervention pro-
tocols [4,5].
Current risk evaluation is derived from epidemiology
investigation upon large populations and assesses the
association of a trait or factor with the clinical out-
come (disease manifestation, progression, etc.). Predic-
tive medicine will modify this approach by introducing
genomic and proteomic profile upon epidemiological
investigation [6,7]. A marker is clinically useful if it
predicts an event or a non-event in 70% of cases. To
reach this goal a strong association between the mar-
ker and a given disease is required with an unadjusted
relative risk or odds ratio = or > 10.0 [8]. A network
of genetic, phenotypic, epidemiological and clinical fac-
tors may reach or go above that level of association
and be very informative for the evaluation of individual
risk for a given CDD.
One area of near future clinical application of these
innovative methodologies is pharmacotherapy with the
goal of optimizing the therapeutic response and minimiz-
ing toxicity and undesired effects [9,10]. For instance,
Transtuzumab, a monoclonal antibody specific for HER2
receptor are only effective in women with HER2 positive
breast cancer subtype [11]. Pharmacogenomic may also
contribute to identify responders to a given drug and
radically modify traditional pharmaceutical trials and dis-
ease’s treatment.
To discuss these topics a one day international meet-
ing entitled “Predictive diagnostics and prevention of
chronic degenerative diseases” was organized by
Dr. Licastro at the Academy of Science of the Bologna
University on December 4th 2009, some of the contri-
butes to the congress have been collected as full papers
and presented in this special issue of Immunity and
Aging.
The paper presented by Dr. Ravaglia and co-worker
illustrate the relevance of longitudinal population study
such as “the Conselice Study on Brain aging” to gather
new markers linked to the risk of cognitive decline and
dementia in old age and validate risk factors described
in other epidemiological investigations.
Dr. Grossi presented a contribution illustrating a new
statistical algorithm derived from artificial adaptive
neural network systems for mining variables from bio-
medical database. This new statistical tool is able to
describe a connectivity map of factors associated with a
disease, the interactions among variables and their rele-
vance with a given disease.
The article from Dr. Licastro and co-workers pre-
sented an application of the artificial adaptive system on
a large number of variables collected from “the Conse-
lice Study on Brain aging” longitudinal population inves-
tigation and showed a connectivity map of variables
associated with the age associated cognitive decline and
dementia.
Dr. Tomasi discussed the role of prion proteins on
cellular kinases and their effects in signal transduction
pathways of neurons in both physiological conditions
and human neurodegneration.
Dr. Ianni and co-workers presented data regarding gly-
cosilation profile of plasma purified alpha-1-antichymo-
trispin (ACT) in patients with Alzheimer’s diseases (AD)
as a model of CDD. Data from previous investigations
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proposed ACT as peripheral marker associated with AD
and Dr. Ianni’s presented paper suggests that a propor-
tion of peripheral ACT may derive from AD brain, as
indicated by the differential glycosilation profile of blood
ACT from these patients.
Paper from Dr. Dogliotti and collaborators reported
data from subjects with Down’s syndrome (DS), a com-
plex human condition characterized by mental retarda-
tion, early presentation of Alzheimer’s disease, immune
defects and increased susceptibility to infections. From
this pilot investigation blood gelatinase is suggested as a
candidate marker of inflammation associated with auto-
immunity that is a frequent pathology in DS patients.
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